Inclusion Criteria:

- Diagnosis of acute myeloid leukemia (AML) according to the 2008 criteria of the World
Health Organization (WHO).18

- all French-American-British (FAB) subtypes, except:

- M3 (acute promyelocytic leukemia)

- all cases of de novo AML or secondary AML with ≥ 20 % blasts in peripheral blood
and/or bone marrow, except:

- AML secondary to myeloproliferative neoplasms (MPN)

- AML secondary to exposure of leukemogenic agents (t-AML).

- WT1 transcript levels in peripheral blood and/or bone marrow increased above
background at the time of diagnosis, as determined by qRT-PCR.

- Completion of at least one cycle of induction chemotherapy and one cycle of
consolidation chemotherapy resulting in:

- morphological complete remission (CR), i.e. bone marrow blast count <5% with
neutrophil count >1000 cells/µL and platelet count >100,000 cells/µL.

OR

o morphological complete remission with incomplete blood recovery (CRi), i.e. bone marrow
blast count <5% with neutrophil count <1000 cells/µL or platelet count <100,000 cells/µL.

For the purpose of this study protocol, platelet count must be >50,000 cells/µL.

- Interval between the completion of the last chemotherapy administration and the start
of vaccination (or the start of follow-up in case of the control arm): 6 weeks
(minimum) and 16 weeks (maximum).

- Age: >65 years at the time of enrollment.

- WHO performance status: grade 0 or 1 at the time of enrollment. For definition of
performance status, see: http://www.ecog.org/general/perf_stat.html

- Absence of any psychological, familial, sociological, geographical or physical
condition potentially hampering compliance with the study protocol and follow-up
schedule; those conditions should be discussed with the patient before study entry.

Exclusion Criteria:

- Participation in any other interventional clinical trial during the study period.

- History or concomitant presence of any other malignancy, except for:

- non-melanoma skin cancer

- carcinoma in situ of the cervix

- any other effectively treated malignancy that has been in remission for >5 years
or that is highly likely to be cured at the time of enrollment.

- Concomitant presence of any immunosuppressive disease (e.g. HIV) or any active
autoimmune condition, except for vitiligo.

- Concomitant use of systemic corticosteroids in immunosuppressive doses (>1 mg/kg/day
of prednisone, or equivalent dose for other corticosteroid preparations) or any other
immunosuppressive agent. A minimum of 4 weeks must have elapsed between the last dose
of immunosuppressive therapy and the first vaccination. Topical corticosteroids are
permitted, except if applied at the sites of DC injection.